- Home
- EDF vs MOLN Comparison
EDF vs MOLN Comparison
Compare EDF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EDF | MOLN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 154.2M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDF | MOLN |
|---|---|---|
| Price | $5.21 | $4.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 100.1K | 976.0 |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $3.47 |
| 52 Week High | $5.67 | $5.36 |
Technical Indicators
Market Signals| Indicator | EDF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 57.37 |
| Support Level | $5.15 | $4.13 |
| Resistance Level | $5.39 | $4.30 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 48.57 | 90.47 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.